Answers are grounded in this paper and cite their sources.
A novel class of 5-substituted 5 H -imidazo[5,1- a ]isoindoles are described as potent inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1). A structure-based drug design approach was used to elaborate the 5 H -imidazo[5,1- a ]isoindole core and to improve potency and pharmacological properties. Suitably placed hydrophobic and polar functional groups in the lead molecule allowed improvement of IDO1 inhibitory activity while minimizing off-target liabilities. Structure–activity relationship studies focused on optimizing IDO1 inhibition potency and a pharmacokinetic profile amenable to oral dosing while controlling CYP450 and hERG inhibitory properties.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: